Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
No one on the platform currently holds KRTX.
No tracked institution reports a position in KRTX as of their last filing.
No one on the platform has traded KRTX yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
@jamesmckevitt $CDTX $KRTX $CRNX ✌️🙏❤️🩹
View on StockTwits ↗
$RVPH Based on industry patterns, Reviva’s profile, and market dynamics, the likelihood of a buyout or M&A (merger/acquisition) is moderate to high (50-70%) within 12-18 months of NDA submission approval. This estimate draws from • Historical Precedents in Schizophrenia Biotechs: Late-stage assets in this space often attract acquirers due to high unmet need and blockbuster potential (e.g., peak sales forecasts for brilaroxazine: $500M-$1B+ annually) • Karuna Therapeutics ($KRTX) filed an NDA for KarXT (similar novel antipsychotic) in 2023; Bristol Myers Squibb (BMS) acquired it for $14B in 2024, just months post-filing, valuing the asset at ~5-7x projected peak sales • Cerevel Therapeutics ($CERE) advanced emraclidine (Phase 3-ready muscarinic agonist); AbbVie bought it for $8.7B in 2024 amid NDA preparations. • These deals highlight Big Pharma’s (BMS, AbbVie, Pfizer) appetite for differentiated schizophrenia candidates to refill pipelines amid patent cliffs (Eliquis, Keytruda)
View on StockTwits ↗
@Covode13 @PDM21 @Rony4AM @richardnj58 @mmtiddy “No upside proves the point”? Not in small-cap biotech. Most real winners looked dead before they ran. Examples: • $KRTX sat under $6 with zero interest → Phase 2 readout → $200+ buyout. • $SRPT traded at $3 for years, called a scam → data hit → $150+. • $IMVT was left for dead under $5 → Phase 2 success → $40+. • $NVCT flat at $1–2 forever → FDA breakthrough designation → 10×. • $APLS was ignored under $4 → Phase 3 approval → $80. Flat price ≠ no value. It’s how small biotechs behave before catalysts. Cardiol now has Phase 3 underway, strong myocarditis MRI data coming, runway to 2027, zero debt, Orphan status in two indications, and a 13-year Eli Lilly CMO running development. This setup is exactly what those small-cap winners looked like right before they rerated hard.
View on StockTwits ↗
MapLight Therapeutics' ( $MPLT ) IPO is Reportedly Well Oversubscribed, Ahead of its Scheduled Pricing on October 26 - Yesterday, As Per Bloomberg/BBG. $KRTX - $BMY https://www.sec.gov/Archives/edgar/data/1770069/000119312525231829/d90027ds1a.htm The current offering is 14.75 million shares at $17 each to raise $250.8 million. The company is expected to stop taking orders Thursday after markets close in New York; the offering is scheduled to price on October 26, according to a management presentation. Morgan Stanley, Jefferies Financial Group Inc., Leerink Partners, and Stifel Financial Corp. are working on the offering. MapLight is pioneering the discovery, development, and delivery of transformative treatments for brain disorders:
View on StockTwits ↗
$RVPH Catalysts Driving Squeeze Risk Upcoming events could ignite covering: November 6-7, 2025: Open-Label Extension (OLE) data presentation for brilaroxazine (schizophrenia drug). November 11-12, 2025: BIO CEO & Investor Conference for visibility. November 17, 2025: Q3 earnings report. December 9, 2025: Neuro Innovation Forum discussing clinical programs. Q4 2025 / Early Q1 2026: Phase 3 interim data readout for brilaroxazine, a major value driver. Recent: $9 million offering (September 2025) and OLE trial completion boosted a 21% surge, with positive data showing efficacy and biomarker improvements. Positive outcomes (e.g., robust efficacy, low discontinuation) could mirror peers like $DRUG or $ALGS, triggering parabolic moves. Buyout chatter adds upside, given $83 million cap vs. acquisitions like $KRTX ($14B).
View on StockTwits ↗
$INSM $ARDX $KRTX Catalyst. Undervalued. Ignored. Q4 = Repricing
View on StockTwits ↗$INSM $ARDX $PLTR $SMCI $KRTX Pipeline catalysis, valuation compression, and AI narrative interweaving, Q4 is a watershed. It is an opportunity
View on StockTwits ↗
$TSLA Folks please focus on $KRTX to fix your Elon derangement syndrome. Also invest in psychological treatment drug companies because the mental illness is stacking up.
View on StockTwits ↗
@sporalysis @stocky1234 I take back that I've never used them. I did place an upside order once - on $KRTX - and missed out BIG time when it exploded and never came back!
View on StockTwits ↗
$KRTX Karuna Therapeutics, Inc. (NASDAQ:KRTX) A Promising Biopharmaceutical Company Advancing Transformative Therapies https://beyondspx.com/article/karuna-therapeutics-inc-nasdaq-krtx-a-promising-biopharmaceutical-company-advancing-transformative-therapies
View on StockTwits ↗
$RVPH https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Presents-New-Pooled-Interim-Long-Term-Safety-and-Metabolic-Outcomes-Data-from-the-EMERGENT-Program-Evaluating-KarXT-in-Schizophrenia-at-the-2024-Annual-Congress-of-the-Schizophrenia-International-Research-Society/default.aspx 15% drop out due to adverse events of $krtx / $bmy drug $RVpH drop out about 1/10 of that
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $711M | +166.1% | $0.50 | $-6.60–$10.79 | 663.3× | 8 |
| 2027 | $1.4B | +98.2% | $12.71 | $12.71–$12.71 | 26.0× | 5 |
| 2028 | $2.5B | +73.8% | $28.54 | $28.54–$28.54 | 11.6× | 6 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2024-05-02 | $-3.06 | $-2.80 | +8.5% |
| 2024-02-22 | $-2.64 | $-3.01 | -14.0% |
| 2023-11-02 | $-2.74 | $-3.16 | -15.3% |
| 2023-08-03 | $-2.76 | $-2.75 | +0.4% |
| 2023-05-04 | $-2.86 | $-2.80 | +2.1% |
| 2023-02-23 | $-2.23 | $-2.22 | +0.4% |
| 2022-11-03 | $-1.99 | $-2.38 | -19.6% |
| 2022-08-08 | $-2.02 | $-2.17 | -7.4% |
| +0.00% |
| $11.5B |
| — |
| IMGNImmunoGen, Inc. | $31.23 | +0.02% | $8.7B | — |
| ISEEIVERIC bio, Inc. | $39.95 | +0.38% | $5.5B | — |
Source: Financial Modeling Prep · peers by sector/industry